A randomized, double-blind, multicenter, phase III study on the efficacy and safety of a combination treatment involving fimasartan, amlodipine, rosuvastatin in patients with essential hypertension and dyslipidemia who fail to respond adequately to fimasartan monotherapy

Table 1 Inclusion criteria and LDL-C goals for therapeutic lifestyle changes

Risk category	Major risk factors^a	LDL-C goal (mg/dL)	LDL-C level (mg/dL)	TG level (mg/dL)
High risk	CHD^b or CHD risk equivalents^c (10-yr risk > 20%)	< 100	≥ 100	< 400
Moderate risk	2 + Risk factors (10 yr risk ≤ 20%)	< 130	≥ 130
Low risk	0–1 Risk factor	< 160	≥ 160

LDL-C Low-density lipoprotein cholesterol, TG Triglyceride, CHD Coronary heart disease, HDL High-density lipoprotein
^a Risk factors: include cigarette smoking, hypertension (blood press ≥ 140/90 mmHg or on antihypertensive medication), low HDL cholesterol (< 40 mg/dL), family history of premature CHD (CHD in male first-degree relative < 55 years of age; CHD in female first-degree relative < 65 years of age), and age (men ≥ 45 years; women ≥ 55 years)
^b CHD includes history of myocardial infarction, unstable angina, stable angina, coronary artery procedures (angioplasty or bypass surgery), or evidence of clinically significant myocardial ischemia
^c CHD risk equivalents include clinical manifestations of noncoronary forms of atherosclerotic disease (peripheral arterial disease, abdominal aortic aneurysm, and carotid artery disease [transient ischemic attacks or stroke of carotid origin or > 50% obstruction of a carotid artery]), diabetes, and 2 + risk factors with 10-year risk for hard CHD > 20%

ISSN: 2056-5909